The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Safety and efficacy of interferon-α in 167 patients with human T-cell lymphotropic virus type 1–associated myelopathy
Abstract
A postmarketing surveillance study was undertaken to investigate the safety and efficacy of interferon-alpha for human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) under routine treatment conditions. A total of 273 cases from 91 medical institutions were registered into the survey. So far, 167 cases had been evaluated for safety and 152 for efficacy. The efficacy evaluation was rated based on clinical symptoms of HAM. Efficacy ratio (rate of patients assessed as "modest to markedly improved" and "mildly improved") at 4 weeks was 66.2%. Factors that significantly affected efficacy ratio at 4 weeks was initial Osame's motor disability score (OMDS) before interferon-alpha therapy and duration and stage of illness. Sustained improvement of OMDS for at least 5 months after stopping interferon-alpha was observed in 11 of 30 patients (36.7%). A total of 536 adverse drug reactions (ADRs) occurred in 146 patients, 46 of which were serious. Because some of these ADRs occurred late, it is necessary to watch out for them during long-term treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Despite favourable clinical effects, the long-term utility of IFN-α is challenged by a high probability of adverse reactions.
“Despite the favourable clinical effects, its long-term utility is challenged by a high probability of adverse reactions [245].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [245]
Citations
Cites
Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis
Nakagawa, M., Nakahara, K., Maruyama, Y., Kawabata, M., Higuchi, I., Kubota, H., Izumo, S., Arimura, K., & Osame, M. (1996) · Journal of Neurovirology · doi:10.3109/13550289609146899 · Cited by 150
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Current State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22
Metadata
- Authors
- Arimura, K., Nakagawa, M., Izumo, S., Usuku, K., Itoyama, Y., Kira, J.-I., & Osame, M.
- Affiliations
- Kagoshima University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Tohoku University (JP)
- Kyushu University (JP)
- Corresponding author
- Nakagawa, Masanori
- ORCID
- Kira, Jun-ichi
- Venue
- Journal of Neurovirology
- Published
- 2007-01
- Volume
- 13
- Issue
- 4
- Pages
- 364-372
- ISSN
- 1355-0284 (ISSN-L)
- 1538-2443
- OpenAlex
- W2138952238
- Cited by
- 31
- References
- 1
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 1 · 2012: 4
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of NeuroVirology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- interferon-alpha, tropical spastic paraparesis, HTLV-1, drug safety, drug efficacy, adverse drug reactions, post-marketing surveillance, long-term treatment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antiviral Agents, Disability Evaluation, Female, Humans, Male, Middle Aged, Product Surveillance, Postmarketing, Retrospective Studies, Human T-lymphotropic virus 1, Paraparesis, Tropical Spastic, Databases, Factual, Treatment Outcome, Interferon-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
